Drug intelligence / Profile preview

VACL

Development stage: Preclinical
Modality: Peptides

Overview

VACL is a tetra-peptide that has been identified as an effective inhibitor of human squalene synthase, an enzyme crucial for cholesterol biosynthesis. With IC50 values near 100 μM, VACL shows potential for development as a hypocholesterolemia agent.

Other names: tetra-peptide VACL

Targets

FDFT1 (Squalene synthase)

Beyond the preview

Go deeper on VACL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VACL.

Explore the full profile